Navigation Links
European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
Date:12/1/2008

EXTON, Pa., Dec. 1 /PRNewswire/ -- BioTrends Research Group, Inc. released its third TreatmentTrends(TM): European Nephrology Report. This report runs parallel to two ongoing studies BioTrends conducts -- TreatmentTrends(TM): US and Canadian Nephrology. The report is based on the results of an on-line survey completed by 200 Nephrologists from the UK, Germany, France, Italy, and Spain. The focus is on the management of renal anemia and hyperphosphatemia.

In the ESA market, Amgen's Aranesp is the market share leader in both dialysis and CKD settings and is perceived to have numerous advantages compared to other ESAs. While the use of biosimilar ESAs did increase in the past six months, this was primarily driven by uptake in the German dialysis market. Almost half of the Nephrologists indicate a high concern with the quality of biosimilar ESAs and there appears to be ambivalence about this class of drugs -- only 20% of Nephrologists agree that they have a good understanding of the differences between biosimilar ESAs and their reference brands. Projected ESA share growth is most favorable for Roche's Mircera, particularly in France and Spain, with the greatest share loss coming from Roche's NeoRecormon. Although Aranesp is expected to see share decreases in almost all markets, Nephrologists project Aranesp will maintain its market leader position in both dialysis and CKD.

In general, IV iron is reserved for patients on hemodialysis with about 65% of those treated receiving a consistent maintenance dose. The use of oral iron is more commonplace than the use of IV iron among CKD patients, but many CKD patients do not receive any iron therapy. Venofer and Ferrlecit are the most familiar brands to Nephrologists with market share varying by country. Newcomer Ferinject (ferric carboxymaltose) has yet to make in-roads with 84% of Nephrologists reporting no experience with the drug.

European Nephrologists rated new agents for hyperphosphatemia as one of the greatest unmet needs for their patients and report that at any given time more than one-third of their dialysis patients are above the target level for phosphorus. Calcium based phosphate binders are the most frequently prescribed binders in both dialysis and CKD, however, there is a high prevalence of combination binder therapy typically involving a calcium based agent combined with Genzyme's Renagel. Future share projections appear to favor Shire's Fosrenol which could be due in part to the diminishing concern with lanthanum absorption.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
6. European Centre for Modern Drug Discovery Established in Hamburg
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... Third Wave Bioactives, LLC announces ... Director, focused on leading new business development and ensuring quality customer experience. ... the food ingredient industry in technical, marketing and sales roles. “Brett’s background working with ...
(Date:6/23/2017)... Frederick, MD (PRWEB) , ... June 23, 2017 ... ... laboratory software solutions provider, announced the latest version of LimitLIS®, its rapidly growing ... designed to speed up user adoption, ensure installation integrity, and provide more customization ...
(Date:6/22/2017)... ... June 21, 2017 , ... Beaker, the industry’s pioneer ... the life sciences industry, today announces a strategic partnership with Alcami Corporation, a ... advantage of Beaker’s expertise in executive recruitment solutions, providing Alcami with access to ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... designating infertility as a disease, bringing new hope for prospective parents who are ... annual meeting to back the World Health Organization’s designation in hopes of changing ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
Breaking Biology News(10 mins):